Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease that affects more than a quarter of the global population and whose prevalence is increasing worldwide due to the pandemic of obesity. Obesity, impaired glucose metabolism, high blood pressure and atherogenic dyslipidemia are risk factors for MASLD. Therefore, insulin resistance may be closely associated with the development and progression of MASLD. Hepatic entry of increased fatty acids released from adipose tissue, increase in fatty acid synthesis and reduced fatty acid oxidation in the liver and hepatic overproduction of triglyceride-rich lipoproteins may induce the development of MASLD. Since insulin resistance also induces atherosclerosis, the leading cause for death in MASLD patients is cardiovascular disease. Considering that the development of cardiovascular diseases determines the prognosis of MASLD patients, the therapeutic interventions for MASLD should reduce body weight and improve coronary risk factors, in addition to an improving in liver function. Lifestyle modifications, such as improved diet and increased exercise, and surgical interventions, such as bariatric surgery and intragastric balloons, have shown to improve MASLD by reducing body weight. Sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to improve coronary risk factors and to suppress the occurrence of cardiovascular diseases. Both SGLT2i and GLP-1 have been reported to improve liver enzymes, hepatic steatosis and fibrosis. We recently reported that the selective peroxisome proliferator-activated receptor-alpha (PPARα) modulator pemafibrate improved liver function. PPARα agonists have multiple anti-atherogenic properties. Here, we consider the pathophysiology of MASLD and the mechanisms of action of such drugs and whether such drugs and the combination therapy of such drugs could be the treatments for MASLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The epidemiology and demographic characteristics of MASLD vary worldwide, usually parallel to the prevalence of obesity; however, a substantial proportion of patients are lean [2].”
BackgroundRandle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 1×
“Furthermore, SGLT2i treatment induced a negative energy balance by excreting glucose into the urine, which may induce alteration of the glucose–FA cycle [130].”
BackgroundEslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572 · cited 1×
“It can achieve significant weight loss, normalization of glucose tolerance [74] and reduce the cardiovascular risk and long-term mortality [75,76].”
BackgroundYounossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · cited 2×
“The global prevalence of MASLD among patients with type 2 diabetes was 55.5% (95%CI, 47.3 to 63.7) and the global prevalence of MASH among individuals with type 2 diabetes was 37.3% (95%CI, 24.7 to 50.0) [8].”
BackgroundMethodInfluentialAdipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“GLP-1RAs increase pancreatic insulin secretion and decreases glucagon in a glucose-dependent manner and delays gastric emptying, which suppresses postprandial hyperglycemia and appetite, resulting in reductions in energy intake and body weight [141–143].”
BackgroundChinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170 · cited 2×
“In addition, PPAR α agonists promote HDL-mediated cholesterol efflux from macrophages via enhanced expression of ABCA1 [103].”
BackgroundNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643 · cited 1×
“The pandemic of obesity and its cardiometabolic consequences contribute to an increased prevalence of MASLD [4].”
BackgroundBorén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524 · cited 1×
“Furthermore, LDL and other cholesterol-rich, apo B-containing lipoproteins, once they become retained and modified within the arterial wall, cause atherosclerosis [58].”
BackgroundBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05039-w · Cited by 487
The AMPK pathway in fatty liver disease
Fang, C., Pan, J., Qu, N., Lei, Y., Han, J., Zhang, J., & Han, D. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.970292 · Cited by 364
Harris, L., Hamilton, S., Azevedo, L. B., Olajide, J., De Brún, C., Waller, G., Whittaker, V., Sharp, T., Lean, M., Hankey, C., et al. (2018) · JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2016-003248 · Cited by 319 · cited 1×
“Intermittent fasting, which includes alternate-day fasting, and other forms of periodic caloric restriction have already received attention from animal research scientists [62,63].”
BackgroundMantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299 · cited 1×
“Meta-analyses showed that GLP-1RA improved liver enzymes [138] and liver histology scores for steatosis and fibrosis [139] and liver fat content using MRI-based techniques [140].”
Roden, M., Stingl, H., Chandramouli, V, Schumann, W. C., Hofer, A., Landau, B. R., Nowotny, P., Waldhäusl, W., & Shulman, G. I. (2000) · Diabetes · doi:10.2337/diabetes.49.5.701 · Cited by 288 · cited 1×
“An increase in FFAs leads to hepatic insulin resistance by interacting with insulin signaling [36,37].”
BackgroundKatsagoni, C. N., Georgoulis, M., Papatheodoridis, G. V., Panagiotakos, D. B., & Kontogianni, M. D. (2017) · Metabolism · doi:10.1016/j.metabol.2016.12.006 · Cited by 270
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240 · cited 2×
“…showed that compared with placebo, the greatest benefit with fibrate treatment was seen in 7389 subjects with high TG levels, where fibrate therapy reduced the risk of vascular events by 25%, and in 5068 subjects with both high TG and low HDL-C levels, where the risk was reduced by 29% [81].”
BackgroundMantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16596 · Cited by 213
Haigh, L., Kirk, C., El Gendy, K., Gallacher, J., Errington, L., Mathers, J. C., & Anstee, Q. M. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.06.037 · Cited by 209 · cited 1×
“Another meta-analysis showed that calorie-restricted interventions had favorable effects on alanine aminotransferase (ALT) ( p 0.001), hepatic steatosis ( p 0.001) and liver stiffness ( p = 0.009) [61].”
BackgroundInfluentialCho, Y., Hong, N., Kim, K.-W., Cho, S., Lee, M., Lee, Y.-H., Lee, Y.-H., Kang, E., Cha, B.-S., & Lee, B.-W. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101645 · Cited by 202
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects
Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224808 · Cited by 153
Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis
Schwartz, E. A., & Reaven, P. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.021 · Cited by 130 · cited 1×
“Via the LPL-mediated removal of TG and the CETP-mediated exchange of TG for cholesterol from LDL and HDL, remnant lipoproteins contain more cholesterol than nascent VLDL [53].”
BackgroundMoreno-Fernandez, M. E., Giles, D. A., Stankiewicz, T. E., Sheridan, R., Karns, R., Cappelletti, M., Lampe, K., Mukherjee, R., Sina, C., Sallese, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93626 · Cited by 106 · cited 1×
“This pathway for FA oxidation generates large amounts of ROS [28].”
BackgroundSargeant, J. A., Gray, L. J., Bodicoat, D. H., Willis, S. A., Stensel, D. J., Nimmo, M. A., Aithal, G. P., & King, J. A. (2018) · Obesity Reviews · doi:10.1111/obr.12719 · Cited by 105 · cited 1×
“Exercise training for about 12 weeks induced an absolute reduction in in-trahepatic TG levels of 3.31% (95%CI, − 4.41 to − 2.2) [71].”
BackgroundInfluentialFuchs, M., & Sanyal, A. J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.019 · Cited by 97 · cited 2×
“Lipotoxic intermediate products cause endoplasmic reticulum stress and ROS formation, which are major factors for the pathogenesis of MASH [39,40].”
BackgroundKrieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91 · cited 2×
“Intestinal GLP-1 is an endogenous satiation signal; its eating effects are primarily mediated by vagal afferents [144].”
BackgroundYamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.066 · Cited by 84 · cited 1×
“Pemafibrate is a novel member of the selective PPAR α modulator family that was designed to have a higher PPAR α agonistic activity and selectivity than existing PPAR α agonists such as fibrates [85].”
BackgroundDong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
Lange, M., Nadkarni, D., Martin, L., Newberry, C., Kumar, S., & Kushner, T. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000212 · Cited by 49
Chandan, S., Mohan, B. P., Khan, S. R., Facciorusso, A., Ramai, D., Kassab, L. L., Bhogal, N., Asokkumar, R., Lopez-Nava, G., McDonough, S., et al. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05084-0 · Cited by 46
Effect of intragastric balloons on liver enzymes: A systematic review and meta-analysis
Popov, V. B., Thompson, C. C., Kumar, N., Ciarleglio, M. M., Deng, Y., & Laine, L. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4178-2 · Cited by 43
Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis
Berg, G., Barchuk, M., Lobo, M., & Nogueira, J. P. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102562 · Cited by 36 · cited 1×
“Compared with the patients before the treatment, patients after the GLP-1RA treatment showed significantly reduced values for hemoglobin A1c, BMI, LDL-C and TG [147].”
Result
Cited by
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review
Cumpian, N. A., Gutierrez, J. A., Wu, W., & Saab, S. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.4769 · Cited by 22
Metadata
- Authors
- Yanai, H., Adachi, H., Hakoshima, M., Iida, S., & Katsuyama, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-10-23
- Volume
- 24
- Issue
- 20
- Pages
- 15473
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4387878772
- Cited by
- 194
- References
- 44
- FWCI
- 32.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.